Daiichi Sankyo Joins LabCentral Community as Platinum Sponsor
"We are delighted to welcome Daiichi Sankyo and their team to the local life sciences community and are honored that they have chosen to partner with LabCentral to meet their strategic mission," said
"
Daiichi Sankyo is focused on bringing medical innovation to patients, and recently introduced the Daiichi Sankyo Research Institute of Boston to collaborate with the local innovation ecosystem of academic researchers, innovators, and entrepreneurs. They are committed to building deeper partnerships with the
About LabCentral
A private, non-profit institution, LabCentral is a launchpad for high potential life-sciences and biotech startups with 243,000 square feet of space across
About Daiichi Sankyo
Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and other diseases with high unmet medical need. For more information, please visit www.daiichisankyo.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/daiichi-sankyo-joins-labcentral-community-as-platinum-sponsor-302313733.html
SOURCE LabCentral
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Envision Energy Advances Southeastern Europe's Wind Market as North Macedonia's Largest Wind Project Reaches Financial Close
- UK universities were delivering Government's Industrial Strategy - years before it was written
- Noto Group Adds Senior Partners Kirsty Schofield and Cody Johns to Expand Global Consumer Practice
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share